Skip to main content

Table 2 PLD dose adjustment in MSHFS patients

From: Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

MSHFS 206 Number
Therapy Neoadjuvant therapy 67
Adjuvant therapy 139
First cycle dose (mg) 70 3
60–69 64
50–59 113
40–49 25
< 39 1
MSHFS appearance cycle 1 18
2 86
3 78
4 24
Cumulative dose at the time of MSHFS (mg) > 199 20
180–199 24
160–179 18
140–159 36
120–139 26
100–119 53
80–99 11
60–79 10
40–59 8
Reduce the dose (%) 20% 42
25% 19
Extension of time (Day) 7 33
6 17
5 39
  1. Abbreviations: MSHFS moderate to severe hand-foot syndrome
\